Treatment for severe COVID patients seeing global shortages
Less than two months after the Food and Drug Administration granted emergency authorization for the treatment Actemra for severely sick COVID-19 patients, there are already global shortages due to an "unprecedented surge in worldwide demand," the manufacturer, Roche, said.
Actemra helps fight the inflammatory immune reaction some COVID-19 patients have with severe infection.
Roche said employees have been "working around the clock" to boost production and distribution.
"Despite all these efforts, the unfortunate reality is that due to the unprecedented surge in worldwide demand -- with US demand spiking to well-beyond 400% of pre-COVID levels over the last two weeks alone -- we will experience shortages of Actemra/RoActemra globally over the weeks and months ahead," Roche said. "This is due to global manufacturing capacity limits, raw material supply constraints, the complex, labour-intensive process of manufacturing biologics and the dynamically evolving nature of the pandemic."
The World Health Organization added Actemra to its list of COVID-19 treatments in July following FDA authorization.
-ABC News' Sasha Pezenik